FOR IMMEDIATE RELEASE: November 11, 2023 In honor of Veterans Day, the Multidisciplinary Association for Psychedelic Studies (MAPS) is highlighting a series of insightful discussions focused on critical …
Many in the MAPS community are grieving the loss and suffering experienced by family, friends, colleagues, and countless others impacted by the Israel-Hamas war. At MAPS, we have been in deep dialogue …
PS2023: The Virtual Trip, produced by the Multidisciplinary Association for Psychedelic Studies (MAPS), has published an additional 40 session videos from Psychedelic Science 2023, showcasing a trove of …
FOR IMMEDIATE RELEASE: September 14, 2023 Results of the second, confirmatory Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder, MAPP2, have been published in Nature Medicine. MAPP2 …
The Multidisciplinary Association for Psychedelic Studies (MAPS) has begun publishing a collection of content from the highly acclaimed Psychedelic Science 2023 conference. PS2023: The Virtual Trip brings …
MAPS and the Steven & Alexandra Cohen Foundation Partner to Support the Development of Psychedelic-Assisted Therapies FOR IMMEDIATE RELEASE: June 22, 2023 TheMultidisciplinary Association for Psychedelic …
FOR IMMEDIATE RELEASE: May 22, 2023 The Multidisciplinary Association for Psychedelic Studies (MAPS) announced the launch of the Global Psychedelic Survey. Co-sponsored by MAPS, SABI Mind, Mind Medicine …
FOR IMMEDIATE RELEASE: April 5, 2023 MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), announced preliminary findings …
Distinctions in Australian MDMA and Psilocybin Policy The Therapeutic Goods Administration (TGA) in Australia recently announced a new policy allowing for the limited use of psychedelic-assisted therapies …
FOR IMMEDIATE RELEASE: February 3, 2023 The Therapeutic Goods Administration (TGA) in Australia announced today that they will permit limited use of certain psychedelic-assisted therapies for the treatment …
The world's most advanced psychedelic-assisted therapy trial has confirmed positive findings in the second Phase 3 trial of MDMA-assisted therapy for PTSD.
On November 30, 2022, the jury in CARLA GATLIN, et al. vs DO LAB INC, et al. found in favor of the plaintiffs on the issues of medical responsibility and damages related to the death of a 20-year old woman …
